research
Top four cancer killer rates ‘fall by a third’
August 18, 2014Research and Development, Sales and Marketing CRUK, Cancer, bowel, charity, lung, prostate, research
Death rates for breast, bowel, lung and prostate cancer combined have fallen by almost a third in the last 20 …
Pharma firms give researchers access
July 22, 2014Research and Development, Sales and Marketing AstraZeneca, GlaxoSmithKline, Janssen R&D, MRC, Pfizer, Takeda, UCB, lilly, research, virtual library
UK researchers are to gain access to compounds from seven pharma companies in a partnership with the Medical Research Council …
AstraZeneca reveals Cambridge plans
July 21, 2014Research and Development, Sales and Marketing AstraZeneca, Cambridge, cbc, research, silicon fen
AstraZeneca’s new international HQ on the Cambridge Biomedical Campus (CBC), due to open in two years’ time, will feature an …
Drug prices defy gravity – until patent expiry
June 23, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing John LaMattina, LaMattina, Pfizer, drug, pharma, pricing, research
How drugs are priced is a hot topic these days, and a new Bloomberg article will cause it to heat-up …
Dementia research ‘achingly slow’
June 20, 2014Research and Development, Sales and Marketing Alzheimer's, Cameron, Parkinson's, Parkinsons, UK, billings, dementia, research
The UK prime minister’s envoy on dementia has described progress on research into the neurodegenerative condition as ‘achingly slow’. Global …
Pfizer opens R&D hub in US Cambridge
June 17, 2014Manufacturing and Production, Research and Development, Sales and Marketing Cambridge, Massachusetts, Pfizer, kit, manufacturing, research
Pfizer has open a new 280,000 sq.ft. R&D hub in Cambridge, Massachusetts which also serves to bring together 1,000 of …
Poll: UK opposed to Pfizer takeover bid of AZ
May 13, 2014Research and Development, Sales and Marketing AstraZeneca, Cameron, Pfizer, UK, buyout, merger, research
The UK’s largest union says a new poll shows that the vast majority of the British public are against Pfizer’s …
‘Bioscience is cornerstone’ of Alderley Park
May 12, 2014Research and Development, Sales and Marketing AZ, AstraZeneca, alderley, msp, research
Manchester Science Parks (MSP), the new owners of the 400-acre Alderley Park facility, has pledged to keep its activities “at …
Pfizer appeals to UK prime minister
May 6, 2014Manufacturing and Production, Sales and Marketing AstraZeneca, Cameron, Pfizer, merger, research
Pfizer has attempted to enlist the help of UK prime minister David Cameron in its campaign to buy AstraZeneca, offering …
AZ video: ‘Why we rejected Pfizer offer’
May 2, 2014Medical Communications, Sales and Marketing AstraZeneca, Pfizer, UK, buyout, merger, research
AstraZeneca has confirmed that it is not for turning when it comes to buyout offers from Pfizer and is happy …
Pfizer/AZ deal would put UK research in jeopardy
May 1, 2014Research and Development, Sales and Marketing AstraZeneca, Cameron, Pfizer, UK, deal, merger, research
The UK’s medical research collective has come together to warn the government that any deal between US giant Pfizer and …
Novartis ponders Horsham site future
April 14, 2014Research and Development, Sales and Marketing Horsham, Novartis, Osborne, PharmaVentures, medcity, research, site
Novartis has hired specialist consultancy firm PharmaVentures to help it decide how to re-use it former Horsham site. This comes …
AstraZeneca opens up research
March 28, 2014Medical Communications, Sales and Marketing AstraZeneca, data, research, transparency, website
AstraZeneca has created a new means of sharing some of its data with scientists, such as its bank of live …
AstraZeneca sells Alderley Park
March 13, 2014Research and Development, Sales and Marketing AstraZeneca, Manchester, Osborne, R&D, alderley park, research
AstraZeneca has sold its former R&D site in Cheshire to a public-private consortium for an undisclosed sum, and expects the …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
